MedTrace Logo

Measurement of Smoking-Induced Neutrophil Activation

NCT00159354 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-10-04

No results posted yet for this study

Summary

Neutrophil involvement in the development of COPD by smokers is well recognised. However not all smokers develop overt lung disease. We have previously shown that uptake of FDG is related to neutrophil activity and can be measured by PET and that uptake is greater in COPD patients than normal subjects. We have also shown that FDG-PET shows inflammatory changes in asymptomatic smokers after cigarette smoking. We plan to investigate the attenuation of this inflammation by steroid tablets and whether FDG PET can demonstrate this. We also wish to establish if similar changes are demonstrated after smoking by COPD patients.

Conditions

Interventions

DRUG

predisolone

Sponsors & Collaborators

Principal Investigators

  • Hazel A Jones, PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Completion
2006-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00159354 on ClinicalTrials.gov